STRATEGI DE-ESKALASI PADA PNEUMONIA

Novita Andayani

Abstract


Abstrak. De-eskalasi antibiotik merupakan cara pengobatan pneumonia yakni pemberian antibiotik awal berspektrum luas dengan probabilitas tinggi mencakup semua patogen yang mungkin kemudian dalam waktu 48-72 jam dilanjutkan dengan pengalihan antibiotik spektrum sempit berdasarkan data mikrobiologi yang dapat mencakup semua kuman penyebab (patogen kausatif). Peran penting pada de-eskalasi adalah pada proses pengambilan keputusan dengan memilih terapi spektrum luas secara empiris dan kebijakan menghentikan terapi antibiotik bila hasil kultur sputum mikroorganisme sudah negatif dan terdapat tanda-tanda awal penyembuhan. Tujuan utama dari de-eskalasi adalah berusaha mengganti rejimen terapi empiris kombinasi menjadi rejimen monoterapi untuk mencegah resistensi selama pengobatan.

Abtract. Antibiotic de-escalation is a way of treating pneumonia by giving broad spectrum antibiotic followed by specific antibiotic after 48-72 hours based on the microbiology data which include every micro organism associated. The important part of de-escalation is the decision of choosing broad spectrum therapy empirically and the decision to stop the antibiotic therapy if the result of sputum culture is negative and the signs of healing start to appear. The main purpose of de-escalation is to try to change the regiment of empirical combination therapy to a single therapy to prevent recystention during medication.


Keywords


De-eskalasi antibiotik, pneumonia Antibiotic de-escalation, pneumonia

Full Text:

PDF

References


Song JH. Treatment recommendations of hospital-acquired pneumonia in Asian countries : first consensus report by the Asian HAP working group. Am J Infect Control. 2008. 36 : 83-92.

American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005. 17 : 388-416.

Rea-Neto A. Youssef NCM. Tuche F. Brunkhorst F. Ranieri VM. Reinhart K. et. al. Diagnosis of ventilator-associated pneumonia. a systematic review of literature. Crit Care Med. 2008. 12 : 1186-97.

Niederman MS. Craven DE. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005. 171 : 388-416.

Chastre J. Fagon J. Ventilator-associated pneumonia: state of the art. Am J Respir Crit Care Med. 2002. 165 : 867-93.

Tejerina E. Frutos-Vivar F. Restrepo MI. Anzueto A. Abroug F. Palizas F. et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care. 2006. 21 : 56-65.

Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian Countries. Am J Infect Control. 2008. 36 : 101-8.

Niederman MS. The Importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Respir and Crit Care Med. 2006. 27 : 45-50.

Kollef MH. Optimizing antibiotic therapy in the Intensive Care Unit setting. Crit Care Med. 2001. 5 : 189-95.

Alvarez-Lerma F. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care Med. 2006. 14 : 1-11.

Niederman MS. The Importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Respir Crit Care Med. 2006. 27 : 45-20.

Hoffken G. Niederman MS. Nosocomial pneumonia the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest. 2002. 122 : 2183-96.

Wunderink RG. Rello J. Cammarata SK. Croos-Dabrera RV. Kollef MH. Linezolid vs vancomycin : analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003. 124 : 1789–97.

Conte JE Jr. Golden JA. Kipps J. Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002. 46 : 1475–80.

American Thoracic Society. Hospital-acquired pneumonia in adults : diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies [consensus statement]. Am J Respir Crit Care Med. 1996. 153 : 1711-25.

Kollef MH. The importance of antimicrobial resistance in hospital-acquires and ventilator-associated pneumonia.Curr Anaest And Crit Care. 2005. 16 : 209-19.

Paul M. Benuri-Silbiger I. Soares-Weiser K. Liebovici L. β-Lactam monotherapy versus β-lactam–aminoglycoside combination therapy for sepsis in immunocompetent patients : systematic review and metaanalysis of randomised trials. BMJ. 2004. 18 : 301-11.

Fartoukh M. Maitre B. Honore S. Cerf C. Zahar JR. Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation : the clinical pulmonary infection score revisited. Am J Respir Crit Care Med. 2003. 168 : 173-9.

Porzecanski I. Bowton DL. Diagnosis and treatment of ventilator-associated pneumonia. Chest. 2006. 130 : 597-604.

Ewig E, Bauer T, Torres A. The pulmonary physician in critical care : nosocomial pneumonia. Thorax. 2002. 57 : 366-71.

Chambers RM. Wilson JW. Estes LL. Computer-based monitoring as a tool for antimicrobial de-escalation. 2008. 3 : 199-205.

American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care. 2001. 163 : 1730-54.

Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care Med. 2008. 12 : 1-5.


Refbacks

  • There are currently no refbacks.



Creative Commons LicenseISSN: 1411-3848E-ISSN: 2579-6372
Copyright© 1987-2017 | ISSN: 1412-1026 | EISSN: 2550-0112 
Jurnal Kedokteran Syiah Kuala is licensed under a Creative Commons Attribution 4.0 International License.

 

Published by:
Fakultas Kedokteran, Universitas Syiah Kuala
 
Jl. Tgk. Tanoh Abee, Kopelma Darussalam,
Banda Aceh, 23111, Indonesia.
Phone: +626517551843 
Email: jks@unsyiah.ac.id


Online Submissions & Guidelines | Editorial Policies | Contact | Statistics | Indexing | Citations